Baker Brothers portfolio, Q2 2026

Baker Bros. Advisors · 13F for the quarter ending Jun 30, 2026

For Q2 2026, Baker Bros. Advisors reported $20B across 84 US-listed positions, led by INCY (17.5%), ONC (12.6%) and RVMD (10.7%). Compared with its filing for Q1 2026, Baker Brothers opened 8 new positions, added to 16, reduced 7 and sold out of 8; 52 positions did not change.

The largest purchase was an addition to RVMD ($353.6M); the largest sale, a reduction of EWTX ($116.8M).

This is the latest filing on file; the main portfolio page shows the same holdings against today's prices.

Reported value
$20B
Positions
84
In the top 10
73%
Filed
Aug 14
2026

Key facts

13F portfolio value
$20BQ2 2026
Positions
84
Largest holding
INCY 17.5%
New positions
8
Sold out
8
Filed
Aug 14, 2026

Holdings as of (Q2 2026), filed with the SEC on . Changes are measured against the filing for Mar 31, 2026. Every tracked investor's Q2 2026 13F.

Bought and sold in Q2 2026

Baker Brothers: buys and sells in Q2 2026
StockMoveSharesSizeOf portfolio
Revolution Medicines IncRVMD▲ Added 20%+1.89M$353.6M1.77%
Insmed IncINSM▲ Added 19%+1.38M$146.6M0.73%
Edgewise Therapeutics IncEWTX▼ Reduced 44%−2.87M$116.8M0.59%
Abivax SAABVX▼ Sold out−875.8K$97.5M0.49%
Summit Therapeutics IncSMMT▼ Reduced 9.9%−3.6M$52.5M0.26%
Spyre Therapeutics IncSYRE▼ Sold out−1M$50.4M0.25%
IDEAYA Biosciences IncIDYA▲ Added 27%+1.06M$39.6M0.20%
Faeth Therapeutics IncFTH▲ New+1.29M$32.2M0.16%
Relay Therapeutics IncRLAY▲ Added 144%+1.67M$31.2M0.16%
Centessa Pharmaceuticals PLCno ticker on file
▼ Sold out−670.75K$26.6M0.13%
Immunocore Holdings plcIMCR▼ Sold out−734.4K$22.1M0.11%
Abcellera Biologics IncABCL▲ Added 9.0%+2.74M$21.5M0.11%
Celldex Therapeutics IncCLDX▲ Added 78%+517.24K$19.2M0.10%
Contineum Therapeutics IncCTNM▼ Sold out−1.42M$18.6M0.09%
argenx SEARGX▼ Sold out−25.17K$18.4M0.09%
Cytokinetics IncCYTK▲ New+211.27K$18M0.09%
Intellia Therapeutics IncNTLA▲ New+930.23K$15.7M0.08%
Immatics N.V.IMTX▼ Reduced 13%−1.41M$14.3M0.07%
Parabilis Medicines IncPBLS▲ New+500K$13.7M0.07%
Arcus Biosciences IncRCUS▲ Added 103%+429.2K$13.2M0.07%
Compass Pathways PlcCMPS▼ Sold out−2.34M$13M0.06%
Avalyn Pharma IncAVLN▲ New+350K$11.5M0.06%
Pharvaris N VPHVS▼ Sold out−375K$10.6M0.05%
Cerus CorpCERS▼ Reduced 36%−3.61M$10.5M0.05%
Tango Therapeutics IncTNGX▲ New+333.33K$10.4M0.05%
Avalo Therapeutics IncAVTX▲ New+550K$10.2M0.05%
Jade Biosciences IncJBIO▼ Reduced 25%−410.71K$9.1M0.05%
Viridian Therapeutics IncVRDN▲ Added 21%+411.35K$7.6M0.04%
Verastem IncVSTM▲ Added 327%+1.91M$7.3M0.04%
Roivant Sciences LtdROIV▼ Reduced 3.1%−150.89K$5.3M0.03%
Incyte CorpINCY▲ Added 0.06%+17.92K$2M0.01%
Design Therapeutics IncDSGN▲ Added 3.6%+92.45K$1.3M0.01%
Immunome IncIMNM▲ New+55.31K$1.2M0.01%
Immunovant IncIMVT▼ Reduced 0.4%−22.66K$873.1K0.00%
Madrigal Pharmaceuticals IncMDGL▲ Added 0.07%+1.43K$767.8K0.00%
Beone Medicines LtdONC▲ Added 0.03%+2.51K$716.4K0.00%
Kiniksa Pharmaceuticals InternationalKNSA▲ Added 0.3%+8.4K$537K0.00%
Acadia Pharmaceuticals IncACAD▲ Added 0.04%+16.21K$410.2K0.00%
Denali Therapeutics IncDNLI▲ Added 0.07%+2.64K$67.9K0.00%

Holdings at the quarter's end

Baker Brothers holdings, Q2 2026
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q1 2026
1Incyte CorpINCYHealth Care17.5%$3.5B30.76M$113.369+ qtrs▲ Added 0.06%
2Beone Medicines LtdONC · SPONSORED ADSHealth Care12.6%$2.5B8.8M$284.979+ qtrs▲ Added 0.03%
3Revolution Medicines IncRVMDHealth Care10.7%$2.1B11.44M$187.289+ qtrs▲ Added 20%
4Madrigal Pharmaceuticals IncMDGLHealth Care5.77%$1.2B2.14M$536.959+ qtrs▲ Added 0.07%
5Acadia Pharmaceuticals IncACAD—5.44%$1.1B42.91M$25.309+ qtrs▲ Added 0.04%
6Kymera Therapeutics IncKYMRHealth Care4.98%$992.7M8.66M$114.679+ qtrsNo change
7Insmed IncINSMHealth Care4.70%$937.8M8.8M$106.629+ qtrs▲ Added 19%
8Celcuity IncCELC—4.15%$828.2M7.92M$104.629+ qtrsNo change
9Kodiak Sciences IncKODHealth Care3.89%$776.1M19.92M$38.969+ qtrsNo change
10Rhythm Pharmaceuticals IncRYTMHealth Care3.12%$622.3M5.6M$111.039+ qtrsNo change
11Praxis Precision MedicinesPRAXHealth Care2.94%$587M1.75M$334.799+ qtrsNo change
12Alkermes PLCALKS · SHSHealth Care2.63%$524.6M10.01M$52.399+ qtrsNo change
13Summit Therapeutics IncSMMTHealth Care2.39%$477.7M32.79M$14.579+ qtrs▼ Reduced 9.9%
14Grail IncGRALHealth Care1.38%$275M4.03M$68.277 qtrsNo change
15Abcellera Biologics IncABCL—1.30%$259.1M33.01M$7.859+ qtrs▲ Added 9.0%
16Immunovant IncIMVTHealth Care1.05%$209.4M5.44M$38.539+ qtrs▼ Reduced 0.4%
17IDEAYA Biosciences IncIDYA—0.94%$186.7M5.01M$37.279+ qtrs▲ Added 27%
18Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL AHealth Care0.91%$181.3M2.83M$63.959+ qtrs▲ Added 0.3%
19Roivant Sciences LtdROIV · SHSHealth Care0.84%$166.9M4.72M$35.399+ qtrs▼ Reduced 3.1%
20Arrowhead PharmaceuticalsARWRHealth Care0.81%$162.4M1.99M$81.515 qtrsNo change
21Ionis Pharmaceuticals IncIONSHealth Care0.81%$162.4M2.05M$79.294 qtrsNo change
22Edgewise Therapeutics IncEWTXHealth Care0.75%$150.4M3.7M$40.639+ qtrs▼ Reduced 44%
23Replimune Group IncREPL—0.61%$122.3M11.05M$11.079+ qtrsNo change
24Nurix Therapeutics IncNRIX—0.57%$113M4.66M$24.269+ qtrsNo change
25Stoke Therapeutics IncSTOK—0.55%$109.2M3.34M$32.729+ qtrsNo change
26Monte Rosa Therapeutics IncGLUE—0.53%$105.2M4.35M$24.209+ qtrsNo change
27Immatics N.V.IMTX · SHS—0.48%$96.3M9.51M$10.139+ qtrs▼ Reduced 13%
28Denali Therapeutics IncDNLI—0.48%$96M3.73M$25.729+ qtrs▲ Added 0.07%
29
Crinetics Pharmaceuticalsno ticker on file
—0.44%$88M2.35M$37.425 qtrsNo change
30Dianthus Therapeutics IncDNTHHealth Care0.42%$83.1M852.16K$97.485 qtrsNo change
31Structure Therapeutics IncGPCR · SPONSORED ADS—0.39%$76.9M1.43M$53.678 qtrsNo change
32
Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031
—0.35%$69.2M——4 qtrs—
33Rapport Therapeutics IncRAPP—0.32%$64.5M1.55M$41.675 qtrsNo change
34Alumis IncALMS—0.28%$56.6M2.01M$28.149+ qtrsNo change
35Prelude Therapeutics IncPRLD—0.27%$54M10.12M$5.339+ qtrsNo change
36Relay Therapeutics IncRLAY—0.27%$52.9M2.83M$18.719+ qtrs▲ Added 144%
37Mirum Pharmaceuticals IncMIRMHealth Care0.26%$52.2M445.98K$117.072 qtrsNo change
38Bicycle Therapeutics PlcBCYC · SPONSORED ADS—0.23%$46.2M10.89M$4.249+ qtrsNo change
39Enliven Therapeutics IncELVN—0.23%$45.9M905.19K$50.759+ qtrsNo change
40Celldex Therapeutics IncCLDX—0.22%$44M1.18M$37.219+ qtrs▲ Added 78%
41Viridian Therapeutics IncVRDN—0.22%$43.8M2.38M$18.375 qtrs▲ Added 21%
42Design Therapeutics IncDSGN—0.19%$38.8M2.68M$14.479+ qtrs▲ Added 3.6%
43Entrada Therapeutics IncTRDA—0.19%$37.3M5.07M$7.369+ qtrsNo change
44Faeth Therapeutics IncFTH—0.16%$32.2M1.29M$25.001 qtrNew
45Aktis Oncology IncAKTS—0.16%$32.1M996.35K$32.232 qtrsNo change
46Neurogene IncNGNE—0.16%$31.2M991.69K$31.459+ qtrsNo change
47Jade Biosciences IncJBIO—0.14%$27.3M1.23M$22.223 qtrs▼ Reduced 25%
48Taysha Gene Therapies IncTSHA—0.14%$27.3M4M$6.819+ qtrsNo change
49Arcus Biosciences IncRCUS—0.13%$26M844.82K$30.833 qtrs▲ Added 103%
50Disc Medicine IncIRON—0.13%$25.6M349.66K$73.147 qtrsNo change
51Absci CorpABSI—0.12%$24.7M2.13M$11.593 qtrsNo change
52Generate Biomedicines IncGENB—0.12%$24M1.42M$16.872 qtrsNo change
53Dbv Technologies S A SponsoredDBVT · SPONSORED ADS—0.12%$24M1.46M$16.409+ qtrsNo change
54Xenon Pharmaceuticals IncXENE—0.11%$22.3M370.21K$60.369+ qtrsNo change
55Tectonic Therapeutic IncTECX—0.11%$20.9M607.79K$34.386 qtrsNo change
56Cerus CorpCERS—0.09%$18.7M6.4M$2.929+ qtrs▼ Reduced 36%
57CytomX Therapeutics IncCTMX—0.09%$18.7M4.98M$3.755 qtrsNo change
58Dyne Therapeutics IncDYN—0.09%$18.1M813.45K$22.213 qtrsNo change
59Cytokinetics IncCYTKHealth Care0.09%$18M211.27K$85.191 qtrNew
60Xencor IncXNCR—0.09%$17.7M1.1M$16.109+ qtrsNo change
61Sionna Therapeutics IncSION—0.09%$17.6M400K$43.996 qtrsNo change
62Intellia Therapeutics IncNTLA—0.08%$15.7M930.23K$16.921 qtrNew
63Parabilis Medicines IncPBLS—0.07%$13.7M500K$27.371 qtrNew
64Maplight Therapeutics IncMPLT—0.07%$13.1M364.71K$35.843 qtrsNo change
65Avalyn Pharma IncAVLN—0.06%$11.5M350K$32.921 qtrNew
66Evommune IncEVMN—0.06%$11.3M847.39K$13.292 qtrsNo change
67BioNTech SEBNTX · SPONSORED ADSHealth Care0.06%$11.1M119.74K$93.057 qtrsNo change
68Tango Therapeutics IncTNGX—0.05%$10.4M333.33K$31.261 qtrNew
69Avalo Therapeutics IncAVTX—0.05%$10.2M550K$18.481 qtrNew
70Sera Prognostics IncSERA · CLASS A COM—0.05%$10M5.5M$1.829+ qtrsNo change
71Verastem IncVSTM—0.05%$9.5M2.5M$3.822 qtrs▲ Added 327%
72Sagimet Biosciences IncSGMT—0.04%$7.4M953K$7.739+ qtrsNo change
73Eikon Therapeutics IncEIKN—0.04%$7.2M555.56K$13.052 qtrsNo change
74LB Pharmaceuticals IncLBRX—0.03%$6.5M200K$32.464 qtrsNo change
75vTv Therapeutics IncVTVT · CL A—0.03%$5.6M148.31K$37.659+ qtrsNo change
76Wave Life Sciences LtdWVE · SHS—0.02%$4.8M822.64K$5.818 qtrsNo change
77Protara Therapeutics IncTARA—0.02%$3.7M971.61K$3.829+ qtrsNo change
78TScan Therapeutics IncTCRX—0.01%$2.7M2.78M$0.98019+ qtrsNo change
79Immunome IncIMNM—0.01%$1.2M55.31K$21.191 qtrNew
80Skye Bioscience IncSKYE—0.01%$1.1M1.58M$0.69339+ qtrsNo change
81Sana Biotechnology IncSANA—0.01%$1.1M310.48K$3.499+ qtrsNo change
82Aligos Therapeutics IncALGS—0.00%$479.2K83.06K$5.779+ qtrsNo change
83Tyra Biosciences IncTYRA—0.00%$338.8K10.61K$31.949+ qtrsNo change
84
Surrozen Incno ticker on file · W EXP 8/11/2026
—0.00%$13.8K833.33K$0.01659+ qtrsNo change

By sector

Baker Brothers portfolio by sector, Q2 2026
SectorShare of portfolioValuePositions
Health Care78.6%$15.7B22
No sector on file21.4%$4.3B62

Questions and answers

What did Baker Brothers own in Q2 2026?

Baker Bros. Advisors's 13F for Q2 2026 lists 84 positions worth $20B. The largest: INCY (17.5%), ONC (12.6%), RVMD (10.7%), MDGL (5.8%), ACAD (5.4%).

What did Baker Brothers buy in Q2 2026?

The largest purchases, by the shares bought at the quarter-end price the filing implies: RVMD (added, $353.6M), INSM (added, $146.6M), IDYA (added, $39.6M), FTH (new, $32.2M), RLAY (added, $31.2M), ABCL (added, $21.5M).

What did Baker Brothers sell in Q2 2026?

The largest sales: EWTX (reduced, $116.8M), ABVX (sold out, $97.5M), SMMT (reduced, $52.5M), SYRE (sold out, $50.4M), Centessa Pharmaceuticals PLC (sold out, $26.6M), IMCR (sold out, $22.1M).

When was this filing made?

Baker Bros. Advisors filed its 13F for the quarter ending Jun 30, 2026 on Aug 14, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Baker Brothers portfolio, Q2 2026: Baker Bros. Advisors 13F holdings”, data as of 14 August 2026. https://funkfolio.com/gurus/baker-brothers/2026-q2

Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Jun 30, 2026.

Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Jun 30, 2026, filed Aug 14, 2026. Changes compare share counts with the filing for Mar 31, 2026; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $20B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 9 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.